Welcome to our dedicated page for Genvor SEC filings (Ticker: GNVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates Genvor Inc. (GNVR) regulatory information and related disclosures, with a focus on how they connect to the company’s peptide-based crop protection and sustainable plant health strategy. While no specific SEC filings are listed in the data provided here, investors typically look to documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand a company’s operations, risk factors, and capital structure.
For a company like Genvor, which operates in the agricultural inputs industry and trades on the OTCQB Venture Market, periodic SEC filings can provide detail on its portfolio of patented and proprietary peptides, its licensing-first business model, and the status of research collaborations with organizations such as the USDA Agricultural Research Service and Tuskegee University. These filings may also discuss intellectual property, Cooperative R&D Agreements, and the development of traits and formulations for crops including corn, citrus, rice, cotton, soybean, flax, and potato.
On Stock Titan, Genvor-related filings are paired with AI-powered summaries designed to highlight key sections, such as disclosures about research milestones, patent issuances, or material agreements. When Forms 10-K and 10-Q are available, AI analysis can help readers quickly identify information about segment focus, R&D activities, and liquidity, while Form 4 insider transaction reports can shed light on trading by directors and officers.
By combining real-time updates from EDGAR with AI-generated explanations, this page aims to make Genvor’s regulatory record easier to navigate for investors, analysts, and others interested in the company’s progress in biological crop protection and plant health technologies.
Genvor Inc. (GNVR) filed a Form 10-K/A correcting a typographical error in its independent auditor's signature date and restating select disclosure items from its 2023 Annual Report. The filing discloses that for the year ended September 30, 2023 the Company recognized a net loss of $1,707,481, had no revenues, and used $871,734 in operating cash, and that these conditions raise substantial doubt about the Companys ability to continue as a going concern. The filing details multiple debt instruments, including a note maturing March 13, 2024 with 10% interest convertible into 134,000 common shares, conversions of $989,000 principal and $146,946 interest into 2,316,147 common shares, and other conversions and warrant issuances. It reports extensive share issuances and transfers across Series A and B preferred and common stock, related-party transactions and settlement terms, net operating loss carryforwards of $2,497,000 and $2,133,000 (available through 2043), deferred tax asset balances, and various contingent liabilities, fees, and subsequent small equity issuances. The filing also references a merger with Old Genvor and settlement payments tied to cancellation of preferred shares.
Genvor Inc. (GNVR) filed a Form 10-K/A correcting a typographical error in its independent auditor's signature date and restating select disclosure items from its 2023 Annual Report. The filing discloses that for the year ended September 30, 2023 the Company recognized a net loss of $1,707,481, had no revenues, and used $871,734 in operating cash, and that these conditions raise substantial doubt about the Companys ability to continue as a going concern. The filing details multiple debt instruments, including a note maturing March 13, 2024 with 10% interest convertible into 134,000 common shares, conversions of $989,000 principal and $146,946 interest into 2,316,147 common shares, and other conversions and warrant issuances. It reports extensive share issuances and transfers across Series A and B preferred and common stock, related-party transactions and settlement terms, net operating loss carryforwards of $2,497,000 and $2,133,000 (available through 2043), deferred tax asset balances, and various contingent liabilities, fees, and subsequent small equity issuances. The filing also references a merger with Old Genvor and settlement payments tied to cancellation of preferred shares.
Genvor Inc. (GNVR) filed a Form 10-K/A correcting a typographical error in its independent auditor's signature date and restating select disclosure items from its 2023 Annual Report. The filing discloses that for the year ended September 30, 2023 the Company recognized a net loss of $1,707,481, had no revenues, and used $871,734 in operating cash, and that these conditions raise substantial doubt about the Companys ability to continue as a going concern. The filing details multiple debt instruments, including a note maturing March 13, 2024 with 10% interest convertible into 134,000 common shares, conversions of $989,000 principal and $146,946 interest into 2,316,147 common shares, and other conversions and warrant issuances. It reports extensive share issuances and transfers across Series A and B preferred and common stock, related-party transactions and settlement terms, net operating loss carryforwards of $2,497,000 and $2,133,000 (available through 2043), deferred tax asset balances, and various contingent liabilities, fees, and subsequent small equity issuances. The filing also references a merger with Old Genvor and settlement payments tied to cancellation of preferred shares.